Overview

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Status:
Terminated
Trial end date:
2018-02-26
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and safety of one dosing regimen in treatment of adult patients with septic shock requiring vasopressor.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals